DESCOVY
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $604,973 | 10 | 0 |
| 2022 | $3.1M | 11 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.7M | 21 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex With Men, and Are at High Risk for HIV-1 Infection | Merck Sharp & Dohme LLC | $3.7M | 0 |
Top Doctors Receiving Payments for DESCOVY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Fort Pierce, FL | $3.7M | 21 |
Manufacturing Companies
- Merck Sharp & Dohme LLC $3.7M
Product Information
- Type Drug
- Total Payments $3.7M
- Total Doctors 0
- Transactions 21
About DESCOVY
DESCOVY is a drug associated with $3.7M in payments to 0 healthcare providers, recorded across 21 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme LLC.
Payment data is available from 2022 to 2023. In 2023, $604,973 was paid across 10 transactions to 0 doctors.
The most common payment nature for DESCOVY is "Unspecified" ($3.7M, 100.0% of total).
DESCOVY is associated with 1 research study, including "A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex With Men, and Are at High Risk for HIV-1 Infection" ($3.7M).